Italfarmaco delivered a presentation at the International Conference on Duchenne and Becker Muscular Dystrophy where their Chief Medical Officer, Dr. Bettica, presented the long term data following patients who have received givinostat in addition to steroid treatment for seven years:
“We are very encouraged to see that the long-term study with Givinostat continues to show a benefit in boys with DMD, which further supports its potential as a treatment. Our Phase 3 pivotal clinical study is on track and continues as planned with 179 boys recruited, and we look forward to announcing the results in the second quarter of next year.”
“We have made significant progress despite the pandemic and instituted procedures to ensure the safety and well-being of all trial participants while being able to continuously provide access to the study drug, as well as to maintain the scientific validity and integrity of the trial. We are grateful to the clinical teams conducting the studies in all of the sites for continuing to work for the benefit of the participants.”Dr. Paolo Bettica
If you have any questions, Duchenne families can email email@example.com to connect with the Italfarmaco team.